Yaxley AJ, et al. – Researchers aimed to compare the detection rates of prostate cancer in men with PIRADS 3–5 abnormalities on 3T mpMRI applying in–bore MRI guided biopsy (MRGB) compared to cognitively directed transperineal biopsy (cTP) and transrectal (cTRUS). No significant difference was observed in the ability to detect CaP or significant CaP applying targeted MRGB, cTP, cTRUS methods. Identification of an abnormal area on mpMRI appears more important in increasing the detection of prostate cancer than the technique applied to biopsy an MRI abnormality.

Methods

• Researchers carried out a retrospective single centre study of consecutive men attending the private practice clinic of an experienced urologist performing MRGB and an experienced urologist performing cTP and cTRUS biopsy techniques for PIRADS 3–5 lesions distinguished on 3T mpMRI.
• They applied SPSS version 22 for statistical analysis.

Results

• It was demonstrated that there were 595 target mpMRI lesions from 482 men with PIRADS 3–5 regions of interest during 483 episodes of biopsy.
• Furthermore, the abnormal mpMRI target lesion was biopsied using the MRGB method for 298 biopsies, cTP method for 248 and by cTRUS for 49 biopsies.
• No significant difference was observed in prostate cancer (CaP) detection between biopsy method in PIRADS 3 (48.9%, 40.0%, 44.4%), PIRADS 4 (73.2%, 81.0%, 85.0%) or PIRADS 5 (95.2, 92.0%, 95.0%) lesions.
• No significant difference was obtained in significant CaP detection between biopsy method in PIRADS 3 (42.2%, 30.0%, 33.3%), PIRADS 4 (66.8%, 66.0%, 80.0%) or PIRADS 5 (90.5%, 89.8%, 90.0%) lesions.
• No difference was found in CaP or significant CaP based on lesion location or size between the methods.